ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2014
Upregulation of serum vascular endothelial growth factor and matrix metalloproteinase-3 in patients with oral squamous cell carcinoma.
Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 16 citations in OpenAlex.
- Identification and validation of potential novel biomarkers for oral squamous cell carcinoma.Bioengineered · 2021Article
- Estimation of serum and salivary matrix metalloproteinase levels in oral squamous cell carcinoma patients: a systematic review and meta-analysis.Postepy dermatologii i alergologii · 2021Review
- Combination of serum matrix metalloproteinase-3 activity and EBV antibodies improves the diagnostic performance of nasopharyngeal carcinoma.Journal of Cancer · 2020Article
- Salivary levels and immunohistochemical expression of selected angiogenic factors in benign and malignant parotid gland tumours.Clinical oral investigations · 2019Article
- Reactive oxygen species-mediated switching expression of MMP-3 in stromal fibroblasts and cancer cells during prostate cancer progression.Scientific reports · 2017Article
- The matrix metalloproteinase and insulin-like growth factor system in oral cancer - a prospective clinical study.OncoTargets and therapy · 2017Article
- MiR-497 enhances metastasis of oral squamous cell carcinoma through SMAD7 suppression.American journal of translational research · 2016Article
- Inhibition of metastasis of oral squamous cell carcinoma by anti-PLGF treatment.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- The functional proteomics analysis of VEGF-treated human epithelial ovarian cancer cells.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vascular endothelial growth factor (VEGF) is known as a fundamental regulator of angiogenesis that accelerates cellular proliferation, vascular permeability, and endothelial cell migration and is an inhibitor of apoptosis. Extracellular matrix degradation by matrix metalloproteinase (MMP) is necessary for endothelial cell proliferation, migration, and metastasis. Accordingly, the objective of the present study was to determine the circulating levels of VEGF and MMP3 and their relation in patients with oral squamous cell carcinoma. Using an ELISA kit, the circulating levels of VEGF and MMP-3 in the sera of 45 patients with oral squamous cell carcinoma (OSCC) and 45 healthy controls were assessed. Mean VEGF levels in the sera of patients with OSCC (122.4 ± 36.1) were significantly higher than those in controls (65.3 ± 23.4); however, no relation was found between VEGF levels and clinicopathologic factors. The serum MMP-3 level in OSCC patients was significantly higher (9.45 ± 4.6 ng/ml, n=45) than that in healthy controls (5.9 ± 3.6 ng/ml, n=45). There was no correlation in serum MMP-3 concentration with clinicopathologic features such as tumor stage, tumor size, nodal status, and histological grade. A significant relationship was found between serum levels of VEGF and MMP3. This study concludes that VEGF and MMP3 may have a potential role in the pathogenesis of OSCC but cannot be used as a tool for monitoring tumor progression. Moreover, the role of VEGF in the regulation of angiogenesis is in part due to activation of MMP-3.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.